期刊文献+

肾性贫血治疗中静脉铁剂的使用现状及其合理用药 被引量:4

下载PDF
导出
摘要 贫血是慢性肾脏病4、5期患者的常见并发症,主要是由于促红细胞生成素(EPO)相对缺乏造成。当重组促红细胞生成素(rh—EPO)制剂在临床中被广泛应用,慢性肾脏病患者的贫血状况得到很好的缓解,但临床观察发现仍有不少患者对EPO的反应性差,反复EPO的应用仍不能很好纠正贫血状况。在排除EPO抗体存在的情况下,对EPO治疗效果差最常见的原因是绝对或相对性铁缺乏。所以铁剂在肾性贫血中的治疗作用被日益肯定。
出处 《预防医学情报杂志》 CAS 2008年第5期390-392,共3页 Journal of Preventive Medicine Information
  • 相关文献

参考文献21

  • 1Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccha -rate as an iron supplement in dialysis patients[ J ]. Nephron, 1996, 72(3) : 413-417.
  • 2路建饶.长期静脉补铁治疗由慢性肾功能衰竭致贫血的随机对照临床研究[J].中国临床药理学杂志,2007,23(4):298-298. 被引量:2
  • 3王海燕 主译.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2003.69-75.
  • 4刘玉村.牛津临床透析手册[M].北京:人民卫生出版社,2006:300-312.
  • 5Riedel MK, Morgenstem T. Iron. replacement in hemodialysis patientswith a normal serum ferritin IeveI[ J ]. Dtsch Med Wochenschr, 2004, 129(36) : 1849-1853.
  • 6St Peter WL, Obrador GT, Robert TL, et al. Trends in intTavenous iron use among dialysis patients in the United States( 1994 -2002) [ J]. Am J Kidney Dis, 2005, 46(4) : 650-660.
  • 7Rogkakou, Guerra, Scordamaglia, et al. Severe skin reaction due to excipients of an oral iron treatment[ J]. Allergy, 2007, 62 ( 3 ) : 334- 335.
  • 8Schaefer LS. ? Dialysis and Transplantation, 2000, 29(4) : 195-197.
  • 9彭爱民,郭玲,杨林,夏荣.蔗糖铁治疗血液透析患者肾性贫血的疗效分析[J].医学综述,2007,13(18):1436-1438. 被引量:1
  • 10李国刚,刘惠兰.静脉补铁在肾性贫血治疗中的应用[J].国外医学(泌尿系统分册),2001,21(2):51-53. 被引量:6

二级参考文献33

  • 1王海燕 主译.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2003.69-75.
  • 2Salahudeen AK,Oliver B,Bower JD,et al.Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis[J].Kidney Int,2001,60:15251531.
  • 3Halliwell B,Chirico S.Lipid peroxidation:Its mechanisms,measurement,and significance[J].Am J Clin Nut,1993 (suppls),57:715-724.
  • 4Fletes R,Lazarus JM,Gage J,et al.Suspected iron dextranrelated adverse drug events in hemodialysis patients[J].Am J Kidney Dis,2001,37:743-749.
  • 5Ryan MJ,Johnson G,Kirk J,et al.HK-2 An immortalized proximal tubule epithelia cell line from normal adult human kidney[J].Kidney Int,1994,45:48-57.
  • 6Prakash M,Upadhya S,Prabhu R.Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron[J].Clin Chim Acta,2005,7:23.
  • 7Reis KA,Guz G,Ozdemir H,et al.Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease[J].Int Heart J,2005,46(3):255-264.
  • 8Saito K,Ishizaka N,Aizawa T,et al.Role of aberrant iron homeostasis in the upregulation of transforming growth factorbeta1 in the kidney of angiotensin Ⅱ-induced hypertensive rats[J].Hypertens Res,2004 Aug,27(8):599-607.
  • 9Shihab FS,Andoh TF,Tanner AM,et al.Expression of apoptosis characterizes cyclosporine Associated interstitial fibrosis[J].Kidney Int,1999,56:2147.
  • 10Horl WH.Should we still use iron dextran in hemodialysis patients[J]?Am J Kidney Dis,2001;37:859-861.

共引文献225

同被引文献38

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部